Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

New England Journal of Medicine - Tập 386 Số 10 - Trang 942-950 - 2022
Gabriel N. Hortobágyi1, Salomon M. Stemmer2, Howard A. Burris3, Yoon Sim Yap4, Gabe S. Sonke5, Lowell L. Hart6, Mario Campone7, Katarína Petráková8, Eric P. Winer9, Wolfgang Janni10, Pierfranco Conté11, David Cameron12, Fabrice André13, Carlos L. Arteaga14, Juan Pablo Zarate15, Arunava Chakravartty15, Tetiana Taran16, Fabienne Le Gac16, Paolo Serra16, Joyce O’Shaughnessy17
1Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Dallas
2Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel
3Sarah Cannon Research Institute, Nashville
4Department of Medical Oncology, National Cancer Centre, Singapore, Singapore
5Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam
6Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers
7Department of Medical Oncology, Institut de Cancérologie de l’Ouest–René Gauducheau, Saint-Herblain
8Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic, the Department of Surgery, Oncology, and Gastroenterology, University of Padua
9Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, the Department of Surgery, Oncology, and Gastroenterology, University of Padua
10Department of Gynecology, University of Ulm, Ulm, Germany, the Department of Surgery, Oncology, and Gastroenterology, University of Padua
11Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy
12Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh
13Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif
14Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas
15Novartis Pharmaceuticals, East Hanover, NJ
16Novartis Pharma, Basel, Switzerland
17Baylor University Medical Center, Texas Oncology, US Oncology, Dallas

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1016/j.ctrv.2017.12.002

10.1007/s10549-013-2711-y

10.1038/nrclinonc.2016.26

Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med 2014;7:203-215.25206307

10.1530/ERC-10-0262

10.1200/JCO.2005.03.7689

10.1158/2159-8290.CD-11-0101

10.1158/1535-7163.MCT-16-0300

10.1016/S1470-2045(15)00613-0

10.1056/NEJMoa1609709

10.1200/JCO.2017.75.6155

10.1016/j.annonc.2020.09.010

National Comprehensive Cancer Network. Metastatic breast cancer. 2020 (https://www.nccn.org/patients/guidelines/content/PDF/stage_iv_breast-patient.pdf).

10.1056/NEJMoa1903765

10.1056/NEJMoa1911149

10.1001/jamaoncol.2019.4782

10.1093/annonc/mdy155

10.1080/03610929108830654

10.1038/s41523-018-0097-z

10.1016/j.annonc.2021.05.353

10.1007/s10549-018-05125-4

10.1158/1538-7445.SABCS20-PD2-04

10.1200/JCO.2021.39.15_suppl.1000

10.1200/JCO.2011.38.1095

10.1016/S1470-2045(13)70322-X

10.1093/annonc/mdu456

10.1200/JCO.2015.61.5831

10.1056/NEJMoa1811714

10.1016/j.annonc.2020.11.011

10.1056/NEJMoa1810527